Organon & Co. Operating Cash Flow
Organon & Co. (OGN) reported Operating Cash Flow of $332.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-31
- Organon & Co. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $107.00M, a 51.36% decline year-over-year.
- Organon & Co. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $225.00M, a 200.00% increase year-over-year.
- Organon & Co. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $141.00M, a 63.85% decline year-over-year.
- Organon & Co. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $264.00M, a 87.23% increase year-over-year.
- Organon & Co. net cash provided by (used in) operating activities for fiscal 2025 was $700.00M, a 25.45% decline from fiscal 2024.
- Organon & Co. net cash provided by (used in) operating activities for fiscal 2024 was $939.00M, a 17.52% increase from fiscal 2023.
- Organon & Co. net cash provided by (used in) operating activities for fiscal 2023 was $799.00M, a 6.88% decline from fiscal 2022.
- Organon & Co. net cash provided by (used in) operating activities for fiscal 2022 was $858.00M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $107.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $332.00M 10-Q · filed 2026-07-31 | $473.00M derived: sum of 3 quarters · filed 2026-07-31 | $737.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $225.00M 10-Q · filed 2026-05-04 | $366.00M derived: sum of 2 quarters · filed 2026-05-04 | $630.00M derived: sum of 3 quarters · filed 2026-05-04 | $850.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $141.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $405.00M derived: sum of 2 quarters · filed 2026-02-24 | $625.00M derived: sum of 3 quarters · filed 2026-07-31 | $700.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $264.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $484.00M derived: sum of 2 quarters · filed 2026-07-31 | $559.00M 10-Q · filed 2025-11-10 | $949.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $220.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $295.00M 10-Q · filed 2026-07-31 | $685.00M derived: sum of 3 quarters · filed 2026-07-31 | $826.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $75.00M 10-Q · filed 2026-05-04 | $465.00M derived: sum of 2 quarters · filed 2026-05-04 | $606.00M derived: sum of 3 quarters · filed 2026-05-04 | $938.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $390.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $531.00M derived: sum of 2 quarters · filed 2026-02-24 | $863.00M derived: sum of 3 quarters · filed 2026-02-24 | $939.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $141.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $473.00M derived: sum of 2 quarters · filed 2025-11-10 | $549.00M 10-Q · filed 2025-11-10 | $946.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $332.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $408.00M 10-Q · filed 2025-08-06 | $805.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.07B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $76.00M 10-Q · filed 2025-05-02 | $473.00M derived: sum of 2 quarters · filed 2026-02-24 | $734.00M derived: sum of 3 quarters · filed 2026-02-24 | $761.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $397.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $658.00M derived: sum of 2 quarters · filed 2026-02-24 | $685.00M derived: sum of 3 quarters · filed 2026-02-24 | $799.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $261.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $288.00M derived: sum of 2 quarters · filed 2024-11-01 | $402.00M 10-Q · filed 2024-11-01 | $669.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $27.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $141.00M 10-Q · filed 2024-08-07 | $408.00M derived: sum of 3 quarters · filed 2025-11-10 | $725.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $114.00M 10-Q · filed 2024-05-03 | $381.00M derived: sum of 2 quarters · filed 2025-11-10 | $698.00M derived: sum of 3 quarters · filed 2025-11-10 | $849.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $267.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $584.00M derived: sum of 2 quarters · filed 2025-11-10 | $735.00M derived: sum of 3 quarters · filed 2025-11-10 | $858.00M 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $317.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $468.00M derived: sum of 2 quarters · filed 2023-11-03 | $591.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $151.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $274.00M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $123.00M 10-Q · filed 2023-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |